Andrew K Godwin, PhD
Chancellors Distinguished Chair in Biomedical Sciences and Endowed Professor
Professor and Director of Molecular Oncology, Pathology and Laboratory Medicine
Deputy Director, The University of Kansas Cancer Center
Director, Biospecimen Repository Core Facility
Kansas Bioscience Authority Eminent Scholar
Publications: Click here
Godwin is a leader in the field of translational research and precision medicine, and members of his research program continue to focus on various aspects of both basic and translational research. He is a NCI funded investigator (continuously since 1993) and a highly published (nearly 500 manuscripts and scholarly review articles) and cited (>60,000 - h-index >128) scientist. Godwin is internationally recognized for his molecular biology/genetic studies of cancers including, sarcoma, breast and ovarian, and his efforts to help bridge the gap between basic and clinical science in order to improve patient care. Through his Clinical Molecular Oncology Laboratory (CMOL) and Biomarker Discovery Laboratory (BDL), Godwin's group continues to support the development and advancement of rationally designed therapeutic strategies to improve the options for patient treated at the KU Cancer Center. His research programs continue to focus on various aspects of both basic and translational research, with an emphasis on early detection of cancer, predictive and prognostic biomarkers, liquid biopsies based on extracellular vesicles (e.g., exosomes), molecular therapeutics, companion diagnostics, clinical trials, and biosample ascertainment.